Arzneimittelforschung 2009; 59(10): 537-540
DOI: 10.1055/s-0031-1296439
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatic
Editio Cantor Verlag Aulendorf (Germany)

Bioequivalence Evaluation of a Fixed Dose Combination Lamivudine + Stavudine Tablet with Concurrent Administration of Lamivudine Tablet and Stavudine Capsule in Healthy Volunteers

Siddarth Chachad
Department of Clinical and Bioequivalence Research Cipla Limited, Mumbai, (India)
,
Amar Lulla
Department of Clinical and Bioequivalence Research Cipla Limited, Mumbai, (India)
,
Geena Malhotra
Department of Clinical and Bioequivalence Research Cipla Limited, Mumbai, (India)
,
Shrinivas Purandare
Department of Clinical and Bioequivalence Research Cipla Limited, Mumbai, (India)
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2011 (online)

Preview

Abstract

The study was designed to compare the rate and extent of absorption of a fixed dose combination tablet of lamivudine (CAS 134678舑17舑4) and stavudine (CAS 3056舑17舑5) with the concurrent administration of lamivudine tablet and stavudine capsule in 24 healthy volunteers under fasting conditions. The volunteers were randomly assigned to the test or reference treatment, with the two treatment periods separated by a washout period of at least 7 days. Plasma samples were analyzed for both analytes lamivudine and stavudine by a validated analytical method. Since the 90% confidence intervals for the “test/reference” mean ratio of the Intransformed pharmacokinetic variables Cmax, AUC0–t and AUC0–∞ were clearly within the conventional bioequivalence range of 80% to 125%, the two treatments were considered bioequivalent. The safety profiles of both the test and reference formulations were comparable.